Antengene's partner Karyopharm announces updated data of Eltanexor for treatment of patients with HMA refractory MDS

Antengene's partner, Karyopharm Therapeutics Inc, announced updated data of eltanexor for the treatment of patients with hypomethylating agent (HMA) refractory myelodysplastic syndrome (MDS) at the 2021 American